Stockholm-based BioTech startup Cellcolabs has raised €10.3 million in new funding to accelerate the industrial-scale production of mesenchymal stem cells (MSCs) and expand its global market presence. The round, led by Titian Capital through its Titian Life Sciences platform, brings Cellcolabs’ total funding to €31 million.

Founded in 2021 by Dr. Mattias Bernow, Cellcolabs is pioneering GMP-certified, high-quality MSC production to make regenerative medicine more accessible and affordable. The company operates a GMP-certified facility in Stockholm, supplying allogeneic MSCs to hospitals, academic institutions, and private clients worldwide. Its proprietary production protocol, inspired by research from Karolinska Institutet, enables large-scale, standardised manufacturing that outpaces traditional models used by industry giants like Lonza and Thermo Fisher Scientific.

The fresh capital will support technical development, production scaling, and IPO readiness, as well as expand its international footprint. Cellcolabs aims to reduce the cost of MSCs by 90% by 2035, driving broader adoption of regenerative therapies.

Dr. Bernow noted, “We are building the infrastructure that can make stem cell therapies widely available in our lifetime.”